{"version":"1.0","type":"link","title":"The efficacy and safety of tislelizumab plus anlotinib as first-line treatment in advanced pulmonary sarcomatoid carcinoma: a single-arm phase II trial.","author_name":"Zeng Z 외","author_url":"https://prs-insight.online/author/Zeng%20Z","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/95228","thumbnail_width":1200,"thumbnail_height":630}